Published in Contemp Oncol (Pozn) on June 18, 2014
Long Non-Coding RNAs in Endometrial Carcinoma. Int J Mol Sci (2015) 0.84
SOX17 increases the cisplatin sensitivity of an endometrial cancer cell line. Cancer Cell Int (2016) 0.77
Prognostic Significance of mTOR and PTEN in Patients with Esophageal Squamous Cell Carcinoma. Biomed Res Int (2015) 0.77
Immunohistochemical expression of glypican 3 in endometrial carcinoma and correlation with prognostic parameters. Int J Clin Exp Pathol (2015) 0.75
SOX17 is a tumor suppressor in endometrial cancer. Oncotarget (2016) 0.75
An update of the classical Bokhman's dualistic model of endometrial cancer. Prz Menopauzalny (2016) 0.75
Genome-wide analysis of gynecologic cancer: The Cancer Genome Atlas in ovarian and endometrial cancer. Oncol Lett (2017) 0.75
Odds ratio analysis in women with endometrial cancer. Prz Menopauzalny (2016) 0.75
FFJ-3 inhibits PKM2 protein expression via the PI3K/Akt signaling pathway and activates the mitochondrial apoptosis signaling pathway in human cancer cells. Oncol Lett (2017) 0.75
p53, the cellular gatekeeper for growth and division. Cell (1997) 31.04
Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell (1997) 21.42
Metformin and reduced risk of cancer in diabetic patients. BMJ (2005) 13.04
The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science (2005) 12.35
Wnt signalling and its impact on development and cancer. Nat Rev Cancer (2008) 8.37
The many ways of Wnt in cancer. Curr Opin Genet Dev (2007) 6.29
Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res (2007) 5.45
PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization. Nat Med (2002) 5.25
Purification and characterization of phosphoinositide 3-kinase from rat liver. J Biol Chem (1990) 4.75
High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. Cancer Res (2005) 3.98
Multisite phosphorylation by Cdk2 and GSK3 controls cyclin E degradation. Mol Cell (2003) 3.91
The v-Jun point mutation allows c-Jun to escape GSK3-dependent recognition and destruction by the Fbw7 ubiquitin ligase. Cancer Cell (2005) 3.47
Casein kinase I transduces Wnt signals. Nature (1999) 3.38
Transcriptional repression of the D-type cyclin-dependent kinase inhibitor p16 by the retinoblastoma susceptibility gene product pRb. Cancer Res (1994) 2.28
The gene for human p53 cellular tumor antigen is located on chromosome 17 short arm (17p13). Proc Natl Acad Sci U S A (1986) 2.18
Only Akt1 is required for proliferation, while Akt2 promotes cell cycle exit through p21 binding. Mol Cell Biol (2006) 2.01
The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies. Cancer Control (2009) 1.96
PIK3R1 (p85α) is somatically mutated at high frequency in primary endometrial cancer. Cancer Res (2011) 1.91
The soluble wnt receptor Frizzled8CRD-hFc inhibits the growth of teratocarcinomas in vivo. Cancer Res (2007) 1.90
Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors. Proc Natl Acad Sci U S A (2012) 1.80
Canonical Wnt signaling is critical to estrogen-mediated uterine growth. Mol Endocrinol (2004) 1.76
CDK4 amplification is an alternative mechanism to p16 gene homozygous deletion in glioma cell lines. Cancer Res (1994) 1.76
The p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis. Cancer Res (1996) 1.55
Wnt signaling in development, disease and translational medicine. Curr Drug Targets (2008) 1.36
Molecular pathology of endometrial carcinoma: practical aspects from the diagnostic and therapeutic viewpoints. J Clin Pathol (2008) 1.31
Concomitant PI3K-AKT and p53 alterations in endometrial carcinomas are associated with poor prognosis. Mod Pathol (2009) 1.28
Molecular pathology of endometrial carcinoma. Histopathology (2013) 1.28
Progesterone inhibition of Wnt/beta-catenin signaling in normal endometrium and endometrial cancer. Clin Cancer Res (2009) 1.15
Endometrial carcinoma: molecular alterations involved in tumor development and progression. Oncogene (2012) 1.14
Down-regulation of Sox7 is associated with aberrant activation of Wnt/b-catenin signaling in endometrial cancer. Oncotarget (2012) 1.12
The β-catenin/TCF complex as a novel target of resveratrol in the Wnt/β-catenin signaling pathway. Biochem Pharmacol (2012) 1.04
Inhibition of AKT with the orally active allosteric AKT inhibitor, MK-2206, sensitizes endometrial cancer cells to progestin. PLoS One (2012) 1.03
Metformin as an addition to conventional chemotherapy in breast cancer. J Clin Oncol (2009) 0.97
Inhibiting the PI3K/Akt pathway reversed progestin resistance in endometrial cancer. Cancer Sci (2011) 0.96
Frizzled-10, up-regulated in primary colorectal cancer, is a positive regulator of the WNT - beta-catenin - TCF signaling pathway. Int J Mol Med (2002) 0.93
The Wnt-dependent signaling pathways as target in oncology drug discovery. Invest New Drugs (2006) 0.93
Cyclin-dependent kinase modulators and cancer therapy. BioDrugs (2012) 0.92
p53 Regulates insulin-like growth factor-I receptor gene expression in uterine serous carcinoma and predicts responsiveness to an insulin-like growth factor-I receptor-directed targeted therapy. Eur J Cancer (2011) 0.91
Role of canonical Wnt signaling in endometrial carcinogenesis. Expert Rev Anticancer Ther (2012) 0.89
Alterations in Wnt-β-catenin and Pten signalling play distinct roles in endometrial cancer initiation and progression. J Pathol (2013) 0.85
The role of p16-cyclin d/CDK-pRb pathway in the tumorigenesis of endometrioid-type endometrial carcinoma. Br J Cancer (2000) 0.85
Expression and the clinical significance of Wnt10a and Wnt10b in endometrial cancer are associated with the Wnt/β-catenin pathway. Oncol Rep (2012) 0.82
The association between p53 expression, stage and histological features in endometrial cancer. Eur J Obstet Gynecol Reprod Biol (2005) 0.80
APC, beta-catenin, and E-cadherin and the development of recurrent endometrial carcinoma. Int J Gynecol Cancer (2004) 0.80
Diagnostic implications of p16 expression in serous papillary endometrial cancer. Int J Gynecol Cancer (2011) 0.78
Identification and characterization of rat Wnt6 and Wnt10a genes in silico. Int J Mol Med (2005) 0.78
[Tyrosine kinases. New target of anticancer therapy]. Postepy Biochem (2005) 0.77
p53 protein overexpression in early stage endometrial cancer. Gynecol Oncol (1996) 0.76